Keay Nakae

Stock Analyst at Chardan Capital

(4.44)
# 312
Out of 5,090 analysts
251
Total ratings
46.09%
Success rate
26.91%
Average return

Stocks Rated by Keay Nakae

Arrowhead Pharmaceuticals
Dec 1, 2025
Maintains: Buy
Price Target: $60
Current: $61.44
Upside: -2.34%
Allurion Technologies
Nov 20, 2025
Maintains: Neutral
Price Target: $2.5
Current: $1.70
Upside: +47.06%
SAB Biotherapeutics
Nov 17, 2025
Maintains: Buy
Price Target: $12
Current: $3.98
Upside: +201.51%
Arbutus Biopharma
Nov 14, 2025
Maintains: Buy
Price Target: $5
Current: $4.42
Upside: +13.12%
Coya Therapeutics
Nov 14, 2025
Maintains: Buy
Price Target: $14
Current: $6.02
Upside: +132.56%
Monopar Therapeutics
Nov 13, 2025
Maintains: Buy
Price Target: $100
Current: $80.38
Upside: +24.41%
Orchestra BioMed Holdings
Nov 13, 2025
Maintains: Buy
Price Target: $20
Current: $4.40
Upside: +354.55%
Korro Bio
Nov 13, 2025
Downgrades: Neutral
Price Target: $25$7
Current: $7.02
Upside: -0.28%
Avidity Biosciences
Nov 11, 2025
Maintains: Neutral
Price Target: $72
Current: $71.63
Upside: +0.52%
ProQR Therapeutics
Nov 4, 2025
Maintains: Buy
Price Target: $4
Current: $2.09
Upside: +91.39%
Maintains: Buy
Price Target: $35
Current: $6.96
Upside: +402.87%
Maintains: Buy
Price Target: $325$400
Current: $458.12
Upside: -12.69%
Maintains: Buy
Price Target: $50$38
Current: $20.28
Upside: +87.38%
Maintains: Buy
Price Target: $5
Current: $1.20
Upside: +316.67%
Downgrades: Neutral
Price Target: $1.25$6
Current: $16.66
Upside: -63.99%
Maintains: Buy
Price Target: $6
Current: $3.85
Upside: +55.84%
Maintains: Buy
Price Target: $10$8
Current: $0.88
Upside: +809.09%
Downgrades: Neutral
Price Target: n/a
Current: $1.03
Upside: -
Maintains: Sell
Price Target: $8$6
Current: $17.87
Upside: -66.42%
Maintains: Buy
Price Target: $1,140$380
Current: $5.17
Upside: +7,250.10%
Maintains: Buy
Price Target: $65$55
Current: $11.90
Upside: +362.18%
Maintains: Neutral
Price Target: $1.25$10
Current: $4.90
Upside: +104.08%
Upgrades: Neutral
Price Target: $100$88
Current: $19.93
Upside: +339.04%
Downgrades: Neutral
Price Target: $0.7$13
Current: $1.22
Upside: +965.57%